Clinical applications of phage-derived sFvs and sFv fusion proteins

被引：17

作者：

Chester, KA ^{[1
]}

Bhatia, J ^{[1
]}

Boxer, G ^{[1
]}

Cooke, SP ^{[1
]}

Flynn, AA ^{[1
]}

Huhalov, A ^{[1
]}

Mayer, A ^{[1
]}

Pedley, RB ^{[1
]}

Robson, L ^{[1
]}

Sharma, SK ^{[1
]}

Spencer, DIR ^{[1
]}

Begent, RHJ ^{[1
]}

机构：

[1] UCL, Dept Oncol, Royal Free & Univ Coll Med Sch, CRC Targeting & Imaging Grp, London NW3 2PF, England

来源：

DISEASE MARKERS | 2000年 / 16卷 / 1-2期

关键词：

antibody targeting; cancer; ADEPT; CEA; sFv; fusion protein;

D O I：

10.1155/2000/672706

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Single chain Fv antibodies (sFvs) have been produced from filamentous bacteriophage libraries obtained from immunised mice. R MFE-23, the most characterised of these sFvs, is reactive with carcinoembryonic antigen (CEA), a glycoprotein that is highly expressed in colorectal adenocarcinomas. MFE-23 has been expressed in bacteria and purified in our laboratory for two clinical trials; a gamma camera imaging trial using I-123-MFE-23 and a radioimmunoguided surgery trial using I-125-MFE-23, where tumour deposits are detected by a hand-held probe during surgery. Both these trials show MFE-2.3 is safe and effective in localising tumour deposits in patients with cancer. We are now developing fusion proteins which use MFE-23 to deliver a therapeutic moiety; MFE-23::CPG2 targets the enzyme carboxypeptidase G2 (CPG2) for use in the ADEPT (antibody directed enzyme prodrug therapy) system and MFE::TNF alpha aims to reduce sequestration and increase tumor concentrations of systemically administered TNF alpha.

引用

页码：53 / 62

页数：10

共 36 条

[1]

Bagshawe K.D., 1995, TUMOUR TARGETING, V1, P17

[2]

Bagshawe KD, 1996, TRANSPLANT P, V28, P3156

[3] First clinical experience with ADEPT [J].